Search clinical trials for: Ineligible for Cisplatin-based Chemotherapy

Total 364426 results

French Innovative Leukemia Organisation
Acute Leukemia French Association

Not yet recruiting

Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine (VENAZA)

AML, Adult

France
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Nasopharyngeal Carcinoma | De-escalation Therapy

China
AbbVie

Recruiting

A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy (VERO)

Acute Myeloid Leukemia

Italy
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
AbbVie

Recruiting

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada (LIVEN)

Acute Myeloid Leukemia

Canada
AbbVie

Recruiting

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece (SURVIVE)

Acute Myeloid Leukemia

Greece
University of Santo Tomas Hospital, Philippines
Philippine Council for Health Research & Development

Not yet recruiting

HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy (HYACINCT)

Locally Advanced Cervical Carcinoma
Cedars-Sinai Medical Center

Recruiting

Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer

HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Nanfang Hospital of Southern Medical University

Recruiting

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Cisplatin | NPC | Carboplatin

China
Dana-Farber Cancer Institute
Pfizer

Recruiting

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Bladder Cancer | Muscle Invasive Bladder Cancer

United States
AbbVie
Genentech, Inc.

Active, not recruiting

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Acute Myeloid Leukemia (AML)

China
Novartis Pharmaceuticals

Active, not recruiting

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Acute Myeloid Leukemia

Italy, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States
AstraZeneca

Completed

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)

Non-small Cell Lung Cancer

Italy, Poland, France, Spain, United States, Russian Federation
Sidney Kimmel Cancer Center at Thomas Jefferson...
Otsuka America Pharmaceutical

Completed

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
University of Kansas Medical Center
National Center for Advancing Translational Sciences (NCATS)

Active, not recruiting

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

Bladder Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
AbbVie

Completed

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets (VALOR)

Acute Myeloid Leukemia

Austria, Switzerland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Nabil Adra
Genentech, Inc.; Indiana University School of Medicine

Terminated

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Urothelial Carcinoma

United States
Genmab

Terminated

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Head and Neck Cancer | Squamous Cell Carcinoma

United Kingdom, Belgium, France
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
Fundacion CRIS de Investigación para Vencer el...
AstraZeneca; Apices Soluciones S.L.

Completed

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO)

Bladder Cancer

Spain
AbbVie

Completed

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Cancer | Acute Myeloid Leukemia (AML)

United States
Janssen Research & Development, LLC

Completed

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Urinary Bladder Neoplasms

United States, Spain
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Costantine Albany
Mayo Clinic

Completed

Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor

Testicular Germ Cell Tumor

United States
University Hospital Inselspital, Berne
AstraZeneca

Terminated

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin (NITIMIB)

Muscle-invasive Bladder Cancer

Switzerland
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Leukemia, Myeloid, Acute

United States, Australia, France, Poland, Taiwan, Belgium, Germany, United Kingdom, Spain, Israel, Turkey, Korea, Republic of, Russian Federation, Sweden
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Terminated

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Bladder Cancer

United States
Oryx GmbH & Co. KG

Completed

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)

HPV-induced Cancers

Germany
University of Sydney
Melbourne Health; Royal Brisbane and Women's Hospital

Unknown

Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation (SCRAMBLE)

Acute Myeloid Leukaemia

Australia
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Not yet recruiting

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

Breast Cancer | HR+/HER2- Breast Cancer
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Adenocarcinoma | Gastroesophageal Junction
San Luigi Gonzaga Hospital
Azienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaborators

Recruiting

Upfront Surgery Versus NeoAdjuvant Chemotherapy Followed by Surgery for Resectable Advanced Gastric Cancer: SNAC Study (SNAC)

Gastric Cancer

Italy
Wuhan University

Not yet recruiting

A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents

Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI363 in Subjects With Advanced Malignancies

Advanced Malignancies

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction (TRACE)

Esophageal Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery in Limited-metastatic G/GEJ Adenocarcinoma (ROSETTE)

Gastric Cancer | GastroEsophageal Cancer

China
Anhui Provincial Cancer Hospital

Recruiting

An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer

Ovarian Cancer

China
Swiss GO Trial Group
Tumor Profiler Center Switzerland

Not yet recruiting

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy (OVPrecision)

Fallopian Tube Neoplasms | Ovarian Neoplasm Epithelial | High-grade Serous Ovarian Carcinoma (HGSOC) | Ovarian Endometrioid Carcinoma

Switzerland
Regeneron Pharmaceuticals

Not yet recruiting

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Fujian Cancer Hospital

Recruiting

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Wuhan University

Not yet recruiting

A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
The First Affiliated Hospital of Henan University...

Not yet recruiting

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

Esophageal Cancer

China
Genelux Corporation
Newsoara Biopharma Co., Ltd.

Not yet recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25))

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Classic Hodgkin Lymphoma
Guangzhou Medical University

Not yet recruiting

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Leptomeningeal Metastasis

China
Guangzhou Medical University

Not yet recruiting

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Leptomeningeal Metastases
Xijing Hospital

Not yet recruiting

Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

Sintilimab | Neoadjuvant Chemotherapy | Locally Advanced Gastric Cancer
Fundación de Investigación Biomédica - Hospital...

Recruiting

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies (PREDI-CGRP)

Migraine

Spain

3

Subscribe